Oncaspar
Payments companies reported to CMS as associated with Oncaspar. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Oncaspar, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Oncaspar
These are the largest totals companies reported as associated with Oncaspar. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Dan Douer | New York, NY | Hematology (Internal Medicine) | $7,206.02 |
| Scott Howard | Memphis, TN | Pediatric Hematology-Oncology | $5,500.00 |
| Wendy Stock | Chicago, IL | Hematology & Oncology | $2,720.00 |
| Edward Pearson | Dallas, TX | Hematology & Oncology | $1,260.00 |
| Omar Arnaout | Boston, MA | Neurological Surgery | $558.17 |
| Laura Retson | Phoenix, AZ | Pediatric Hematology-Oncology | $135.32 |
| Charlotte Schwalbach | Phoenix, AZ | Pediatrics (Nurse Practitioner) | $135.32 |
| Mary Butler Ching | Phoenix, AZ | Pediatrics (Nurse Practitioner) | $135.32 |
| Michael Henry | Phoenix, AZ | Pediatric Hematology-Oncology | $135.32 |
| Dana Salzberg | Phoenix, AZ | Pediatric Hematology-Oncology | $135.32 |
Prescribed Oncaspar?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.